Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT07576751
Recruiting Observational

Physiotherapy Practice in Flemish Nursing Homes

NCT07576751 · tracked via the Priya Life Science Belgium tracker
Phase
Observational
Started
2026-03-23
Last updated
2026-05-08

Condition(s) studied

Guideline ImplementationPhysiotherapyNursing HomesFocus Group

Investigational drug(s) / intervention(s)

Mapping therapy sessions

Mapping therapy sessions: Mapping therapy sessions provided by physical therapists in Flemish nursing homes

Study summary

The goal of this observational study is to evaluate the extent to which physiotherapy sessions in Flemish nursing homes adhere to the IAGG-GARN guidelines and to explore factors influencing clinical practice among physiotherapists.

The study targets multiple nursing homes across Flanders, with 3 to 5 centers in each of the provinces of Limburg, Antwerp, and Flemish Brabant. This selection ensures variation in geographic location and organizational context. The participants in this study are physiotherapists working in the participating nursing homes.

The main questions it aims to answer are:

* To what extent do the physiotherapy sessions align with the IAGG-GARN guidelines?
* Are there differences in physiotherapy session content and volume according to physiotherapist characteristics and resident characteristics?
* What barriers and facilitators do physiotherapists experience when implementing guideline-based practice in Flemish nursing homes?

Researchers will observe physiotherapy sessions delivered as part of routine care and document session content and duration using structured observation diaries. Participating physiotherapists will also take part in focus groups discussing experiences with guideline implementation, barriers, facilitators, and clinical decision-making.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * None beyond being a licensed physiotherapist working in a Flemish nursing home and willing to participate. Exclusion Criteria: * None

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Nursing home Deurne Antwerpen Not Yet Recruiting
Nursing home Zoersel Antwerpen Recruiting
Nursing home Tongeren Limburg Recruiting

More Hasselt University trials in Belgium

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07576751 on ClinicalTrials.gov ↗ ← All trials in Belgium